Henrietta Konwea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Henrietta Konwea has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Chris Bojke
University of Leeds
3 shared publications - Howard Collier
Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
3 shared publications - Rachael Gilberts
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
3 shared publications - Sarah Tess Brown
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
3 shared publications - Angela Oates
Leeds Beckett University Leeds UK
2 shared publications - Colin Charles Everett
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
2 shared publications
Latest Publications
- Open Access
Pragmatic randomised controlled trial to evaluate the clinical and cost-effectiveness of compression therapy for surgical wounds healing by secondary intention following excision of lower limb keratinocyte cancers in UK skin cancer surgery centres (HEALS2 trial): study protocol
Introduction: Keratinocyte cancers (KCs) are increasing in incidence in the UK, with over 234 000 cases annually, largely due to demographic changes and sun exposure. Skin cancers, including malignant melanoma and KCs, are projected to cost the NHS over £180 million annually and impose healthcare demands. Although KCs have high cure rates following surgical excision and primary closure, wounds healing by secondary intention (HBSI) particularly on the lower leg present clinical challenges. Compression therapy (CT) known to improve venous insufficiency and venous ulcer healing may also benefit HBSI following lower limb KC excision but current evidence is sparse. Methods and analysis: H ealing of E xcision A l wounds on L ower legs by S econdary intention (HEALS2) is a multicentre, prospective, Phase III, parallel group, open-label, randomised controlled trial with embedded internal pilot and blinded endpoint assessment. A total of 396 participants (≥18 years) from UK skin cancer surgery centres will be randomised 1:1 to assess the clinical and cost-effectiveness of standard care (SC) alone or with CT (SC+CT) for surgical wounds HBSI following excision of lower limb KCs. The primary outcome is time to healing from randomisation (maximum 52-week follow-up). Secondary outcomes include incidence of infection, antibiotic usage, scar quality, safety (including complications and hospitalisations), quality of life, cost-effectiveness and relationship between post-partial closure wound area, type of partial closure method and time to healing. Exploratory objectives include association between short-term wound area reduction and time to HBSI, patient acceptability, adherence and associations between wound breakdown post-healing and CT use. A qualitative sub-study will explore patients’ experiences and decision-making during CT use. Primary endpoint analysis will be conducted on the intention-to-treat population using a multivariable Cox Proportional Hazards modelling. Secondary outcomes and safety will be evaluated using other regression models and descriptive statistics, respectively. Cost-effectiveness will be evaluated using within-trial analysis and decision-analytic modelling. Patient and public involvement representatives are contributing to trial design and oversight. The study protocol complies with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Statement. Ethics and dissemination: Ethics approval has been granted by the Yorkshire & The Humber – Leeds East Research Ethics Committee (ref 23/YH/0247). Findings will be published in high-impact peer-reviewed journals. Trial registration number: ISRCTN12417689 .
Open AccessPragmatic randomised controlled trial to evaluate the clinical and cost-effectiveness of compression therapy for surgical wounds healing by secondary intention following excision of lower limb keratinocyte cancers in UK skin cancer surgery centres (HEALS2 trial): study protocol
Introduction: Keratinocyte cancers (KCs) are increasing in incidence in the UK, with over 234 000 cases annually, largely due to demographic changes and sun exposure. Skin cancers, including malignant melanoma and KCs, are projected to cost the NHS over £180 million annually and impose healthcare demands. Although KCs have high cure rates following surgical excision and primary closure, wounds healing by secondary intention (HBSI) particularly on the lower leg present clinical challenges. Compression therapy (CT) known to improve venous insufficiency and venous ulcer healing may also benefit HBSI following lower limb KC excision but current evidence is sparse. Methods and analysis: H ealing of E xcision A l wounds on L ower legs by S econdary intention (HEALS2) is a multicentre, prospective, Phase III, parallel group, open-label, randomised controlled trial with embedded internal pilot and blinded endpoint assessment. A total of 396 participants (≥18 years) from UK skin cancer surgery centres will be randomised 1:1 to assess the clinical and cost-effectiveness of standard care (SC) alone or with CT (SC+CT) for surgical wounds HBSI following excision of lower limb KCs. The primary outcome is time to healing from randomisation (maximum 52-week follow-up). Secondary outcomes include incidence of infection, antibiotic usage, scar quality, safety (including complications and hospitalisations), quality of life, cost-effectiveness and relationship between post-partial closure wound area, type of partial closure method and time to healing. Exploratory objectives include association between short-term wound area reduction and time to HBSI, patient acceptability, adherence and associations between wound breakdown post-healing and CT use. A qualitative sub-study will explore patients’ experiences and decision-making during CT use. Primary endpoint analysis will be conducted on the intention-to-treat population using a multivariable Cox Proportional Hazards modelling. Secondary outcomes and safety will be evaluated using other regression models and descriptive statistics, respectively. Cost-effectiveness will be evaluated using within-trial analysis and decision-analytic modelling. Patient and public involvement representatives are contributing to trial design and oversight. The study protocol complies with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Statement. Ethics and dissemination: Ethics approval has been granted by the Yorkshire & The Humber – Leeds East Research Ethics Committee (ref 23/YH/0247). Findings will be published in high-impact peer-reviewed journals. Trial registration number: ISRCTN12417689 .
- Open Access
- 1 November 2025
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 29 (59) , 1-53
Swabs versus tissue samples for infected diabetic foot ulcers: the CODIFI2 RCT
Background: Foot ulcers affecting people with diabetes (diabetic foot ulcers) often become infected, potentially leading to amputation. Suspected diabetic foot ulcer infection is treated with immediate empiric antimicrobials, with wound samples for culture and sensitivity collected to optimise antibiotic therapy. Collecting samples with swabs is easier than obtaining tissue, but this reports fewer pathogens and more contaminants. Compared with standard culture and sensitivity laboratory methods, molecular microbiology identifies more organisms. How these differences affect clinical decisions or outcomes is currently unknown. Objectives: Main study: To determine if taking tissue samples versus swabs from suspected infected diabetic foot ulcer affects ulcer healing, antibiotic prescribing, costs of care and patient safety. Substudy 1: To determine the agreement between microbiology results from culture and sensitivity versus molecular techniques and to assess whether intention of prescribers to change antimicrobials differs based on sampling methods. Substudy 2: A health-economic perspective of the expected application of empiric and/or targeted treatment regimens and the cost consequences of treatment decisions based on substudy 1. Substudy 3: To compare questionnaire response rates for theoretically informed versus standard participant letters. Substudy 4: To explore clinician perspectives on diabetic foot ulcer sampling and processing techniques. Design: Main study: Randomised controlled trial of results of performing tissue sampling versus swabbing of wounds in people with suspected mild or moderate infected diabetic foot ulcer. Individually randomised (allocation concealed), 1 : 1, tissue or swab sampling for suspected diabetic foot ulcer infection. Follow-up is 12–24 months. A priori sample size estimate is 730. Substudy 1: Cross-sectional agreement study of microbiology results from molecular versus culture and sensitivity techniques and virtual clinic. Diabetic foot ulcers sampled for standard microbiology and central laboratory analysis (molecular). Substudy 2: Exploratory cost–consequence analysis of molecular processing and the likelihood of empiric and targeted treatment based on treatment decisions from substudy 1. Substudy 3: Randomised trial of theoretically informed versus standard participant letters. Substudy 4: Qualitative study explored clinicians’ perspectives regarding sampling and processing techniques. Setting and participants: Twenty-one United Kingdom diabetic foot ulcer clinics. Participants with suspected mild or moderate infected diabetic foot ulcers. Main outcome measures: Main study: Time to ulcer healing (primary outcome blinded assessment), proportion of ulcers healed, antibiotic usage, ulcer area reduction at 4 weeks, hospitalisation duration, time to death, quality of life and cost-effectiveness. Substudy 1: Extent of agreement regarding presence or absence of pathogens from standard versus molecular microbiology. Decision to revise antimicrobials based on sampling method. Substudy 2: Modelled costs (from virtual clinic) of antimicrobial change for standard or molecular analysis. Substudy 3: Response rate for questionnaires. Results: The trial was stopped early, after enrolling only 149 participants, due to poor recruitment. Main study: The hazard ratio for wound healing for patients undergoing tissue versus swab sampling was 1.01 (95% confidence interval 0.65 to 1.55). The swab group had both higher quality-adjusted life-years and lower costs across most time points. Substudy 1: Agreement between culture and sensitivity and molecular microbiology was low. A higher proportion of molecular versus culture and sensitivity vignettes led to recommendations to change antimicrobials [difference 20.5% (95% confidence interval 8.9% to 31.1%)]. Substudy 2: The modelled costs of molecular processing versus culture and sensitivity were £120 higher per wound. Substudy 3: Response rates were 14.8% higher at 52 weeks (95% confidence interval −3.2% to 31.2%) using a theoretically informed versus standard cover letter. Substudy 4: Clinicians were not confident about replacing culture and sensitivity with molecular microbiology, as the result reporting was unfamiliar to them. Limitations: The trial was underpowered. Conclusions: Trial recruitment was challenging during the COVID pandemic and its aftermath. While the results leave substantial uncertainty regarding differences in healing between the sampling methods, tissue sampling appeared to be costlier and was associated with lower quality-adjusted life-years than swabbing. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/163/04.
- 1 November 2025
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 29 (59) , 1-53
Open AccessSwabs versus tissue samples for infected diabetic foot ulcers: the CODIFI2 RCT
Background: Foot ulcers affecting people with diabetes (diabetic foot ulcers) often become infected, potentially leading to amputation. Suspected diabetic foot ulcer infection is treated with immediate empiric antimicrobials, with wound samples for culture and sensitivity collected to optimise antibiotic therapy. Collecting samples with swabs is easier than obtaining tissue, but this reports fewer pathogens and more contaminants. Compared with standard culture and sensitivity laboratory methods, molecular microbiology identifies more organisms. How these differences affect clinical decisions or outcomes is currently unknown. Objectives: Main study: To determine if taking tissue samples versus swabs from suspected infected diabetic foot ulcer affects ulcer healing, antibiotic prescribing, costs of care and patient safety. Substudy 1: To determine the agreement between microbiology results from culture and sensitivity versus molecular techniques and to assess whether intention of prescribers to change antimicrobials differs based on sampling methods. Substudy 2: A health-economic perspective of the expected application of empiric and/or targeted treatment regimens and the cost consequences of treatment decisions based on substudy 1. Substudy 3: To compare questionnaire response rates for theoretically informed versus standard participant letters. Substudy 4: To explore clinician perspectives on diabetic foot ulcer sampling and processing techniques. Design: Main study: Randomised controlled trial of results of performing tissue sampling versus swabbing of wounds in people with suspected mild or moderate infected diabetic foot ulcer. Individually randomised (allocation concealed), 1 : 1, tissue or swab sampling for suspected diabetic foot ulcer infection. Follow-up is 12–24 months. A priori sample size estimate is 730. Substudy 1: Cross-sectional agreement study of microbiology results from molecular versus culture and sensitivity techniques and virtual clinic. Diabetic foot ulcers sampled for standard microbiology and central laboratory analysis (molecular). Substudy 2: Exploratory cost–consequence analysis of molecular processing and the likelihood of empiric and targeted treatment based on treatment decisions from substudy 1. Substudy 3: Randomised trial of theoretically informed versus standard participant letters. Substudy 4: Qualitative study explored clinicians’ perspectives regarding sampling and processing techniques. Setting and participants: Twenty-one United Kingdom diabetic foot ulcer clinics. Participants with suspected mild or moderate infected diabetic foot ulcers. Main outcome measures: Main study: Time to ulcer healing (primary outcome blinded assessment), proportion of ulcers healed, antibiotic usage, ulcer area reduction at 4 weeks, hospitalisation duration, time to death, quality of life and cost-effectiveness. Substudy 1: Extent of agreement regarding presence or absence of pathogens from standard versus molecular microbiology. Decision to revise antimicrobials based on sampling method. Substudy 2: Modelled costs (from virtual clinic) of antimicrobial change for standard or molecular analysis. Substudy 3: Response rate for questionnaires. Results: The trial was stopped early, after enrolling only 149 participants, due to poor recruitment. Main study: The hazard ratio for wound healing for patients undergoing tissue versus swab sampling was 1.01 (95% confidence interval 0.65 to 1.55). The swab group had both higher quality-adjusted life-years and lower costs across most time points. Substudy 1: Agreement between culture and sensitivity and molecular microbiology was low. A higher proportion of molecular versus culture and sensitivity vignettes led to recommendations to change antimicrobials [difference 20.5% (95% confidence interval 8.9% to 31.1%)]. Substudy 2: The modelled costs of molecular processing versus culture and sensitivity were £120 higher per wound. Substudy 3: Response rates were 14.8% higher at 52 weeks (95% confidence interval −3.2% to 31.2%) using a theoretically informed versus standard cover letter. Substudy 4: Clinicians were not confident about replacing culture and sensitivity with molecular microbiology, as the result reporting was unfamiliar to them. Limitations: The trial was underpowered. Conclusions: Trial recruitment was challenging during the COVID pandemic and its aftermath. While the results leave substantial uncertainty regarding differences in healing between the sampling methods, tissue sampling appeared to be costlier and was associated with lower quality-adjusted life-years than swabbing. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/163/04.
- Open Access
- 27 February 2025
- Published by Wiley in Diabetic Medicine
- Vol. 42 (5) , e15492
Cost‐effectiveness of swab versus tissue sampling for infected diabetic foot ulcers from the CODIFI2 randomised controlled trial
Aims: To compare the cost‐effectiveness of wound swabbing versus tissue sampling for infected diabetic foot ulcers.Methods: This multi‐centre, Phase III, prospective, unblinded, two‐arm parallel group, randomised controlled trial compared clinical (reported elsewhere) and economic outcomes of swab versus tissue sampling over a 52–104 week period.Resource use was logged using case record forms and patient questionnaire at weeks 4, 12, 26, 39, 52 and 104, costed using laboratory and published sources from the UK NHS perspective, at 2021/2022 price‐year. EQ‐5D‐3L questionnaires issued at these time points were used to derive quality‐adjusted life‐years (QALYs).To account for imbalances such as age, a regression‐based approach was used to estimate survival, expected costs and QALYs between the sampling arms. Available case analysis (ACA) and multiple imputation methods were applied for self reported missing data, and ACA for researcher‐collected data (survival, hospitalisations and antibiotic use). Probabilistic sensitivity analysis was used to assess the uncertainty of economic results.Results: We recruited 149 participants (75 swab, 74 tissue) from 21 UK sites, between 07 May 2019 and 28 April 2022 (last follow‐up 28 April 2023). Planned sample size was 730 participants, for 90% power to detect 12.5% difference in healing at 52 weeks, but the trial stopped early due to low recruitment.Expected QALYs in the swab‐sampling arm were greater than in the tissue‐sampling arm at weeks 26, 52 and 104.The cost of tissue sampling was greater than of swabbing when including antibiotics and hospitalisation. Swab sampling participants had higher QALYs and lower costs across weeks 26–52, reducing slightly by week 104.Conclusions: Because of higher costs, lower QALYs and lack of evidence of benefit, potentially due to the trial being underpowered, tissue sampling was dominated by wound swabbing in the cost‐effectiveness analysis.
- 27 February 2025
- Published by Wiley in Diabetic Medicine
- Vol. 42 (5) , e15492
Open AccessCost‐effectiveness of swab versus tissue sampling for infected diabetic foot ulcers from the CODIFI2 randomised controlled trial
Aims: To compare the cost‐effectiveness of wound swabbing versus tissue sampling for infected diabetic foot ulcers.Methods: This multi‐centre, Phase III, prospective, unblinded, two‐arm parallel group, randomised controlled trial compared clinical (reported elsewhere) and economic outcomes of swab versus tissue sampling over a 52–104 week period.Resource use was logged using case record forms and patient questionnaire at weeks 4, 12, 26, 39, 52 and 104, costed using laboratory and published sources from the UK NHS perspective, at 2021/2022 price‐year. EQ‐5D‐3L questionnaires issued at these time points were used to derive quality‐adjusted life‐years (QALYs).To account for imbalances such as age, a regression‐based approach was used to estimate survival, expected costs and QALYs between the sampling arms. Available case analysis (ACA) and multiple imputation methods were applied for self reported missing data, and ACA for researcher‐collected data (survival, hospitalisations and antibiotic use). Probabilistic sensitivity analysis was used to assess the uncertainty of economic results.Results: We recruited 149 participants (75 swab, 74 tissue) from 21 UK sites, between 07 May 2019 and 28 April 2022 (last follow‐up 28 April 2023). Planned sample size was 730 participants, for 90% power to detect 12.5% difference in healing at 52 weeks, but the trial stopped early due to low recruitment.Expected QALYs in the swab‐sampling arm were greater than in the tissue‐sampling arm at weeks 26, 52 and 104.The cost of tissue sampling was greater than of swabbing when including antibiotics and hospitalisation. Swab sampling participants had higher QALYs and lower costs across weeks 26–52, reducing slightly by week 104.Conclusions: Because of higher costs, lower QALYs and lack of evidence of benefit, potentially due to the trial being underpowered, tissue sampling was dominated by wound swabbing in the cost‐effectiveness analysis.